Polyclonal heterogeneity: the new norm for secondary clinical resistance to targeted monotherapy in relapsed leukemia?
- Author(s)
- Wei, AH; Roberts, AW;
- Details
- Publication Year 2019-08,Volume 9,Issue #8,Page 998-1000
- Journal Title
- Cancer Discovery
- Publication Type
- Journal Article
- Abstract
- In this issue, McMahon and colleagues demonstrate that secondary clinical resistance to the FLT3 inhibitor gilteritinib in relapsed acute myeloid leukemia is often polyclonal and commonly mediated by heterogeneous mutations that activate downstream RAS-MAPK pathways. These findings and recent data from others indicate that emergence of multiple clones, each with distinct mechanisms of resistance, is a common finding at secondary failure of single-agent-targeted therapies for relapsed leukemias.See related article by McMahon et al., p. 1050.
- Publisher
- AACR
- Research Division(s)
- Bioinformatics; Blood Cells And Blood Cancer
- PubMed ID
- 31371322
- Publisher's Version
- https://doi.org/10.1158/2159-8290.CD-19-0575
- NHMRC Grants
- NHMRC/1079560,
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2019-08-13 12:35:09
Last Modified: 2019-08-13 12:56:12